CEL SCI CORP

Analysis for Ticker: CVM

Cel Sci Corporation operates as a biological host for clinical research that exists to convert shareholder money into administrative salaries and facility fees rather than commercial revenue. The company is currently in a state of financial collapse, admitting in its latest 05/2026 filings that it suffers from material weaknesses in its accounting and has substantial doubt it can survive for another year. They are currently attempting to extract 15,0$ million from the public through a new stock offering, but the math for any new investor is a disaster. If you buy a share at the target price of 3,07$, its actual tangible worth is only 1,91$, meaning 1,16$ of your money vanishes into the corporate deficit the moment you pay. This transaction will instantly dilute current owners by more than 50,0% while the company pays a 7,0% commission plus 185.000$ in fees to ThinkEquity LLC just to handle the sale. With cash reserves running dry and quarterly expenses exceeding 5,0$ million, they are desperate to fund a 30,0$ million to 35,0$ million study because their previous clinical efforts failed to get the drug approved for most patients.